|
1
|
Vanlet P, Horny HP, Bennet JM, Fonatsch C,
Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O,
et al: Definitions and standards in the diagnosis and treatment of
myelodysplastic syndromes: Consensus statements and report from a
working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar
|
|
2
|
AdèS L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar
|
|
3
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar
|
|
4
|
Malcovati L, Germing U, Kuendgen A, Della
Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B,
Bernasconi P, Knipp S, et al: Time-dependent prognostic scoring
system for predicting survival and leukemic evolution in
myelodysplastic syndromes. J Clin Oncol. 25:3503–3510. 2007.
View Article : Google Scholar
|
|
5
|
Neukirchen J, Schoonen WM, Strupp C,
Gattermann N, Aul C, Haas R and Germing U: Incidence and prevalence
of myelodysplastic syndromes: Data from the Düsseldorf
MDS-registry. Leuk Res. 35:1591–1596. 2011. View Article : Google Scholar
|
|
6
|
Zeidan AM, Shallis RM, Wang R, Davidoff A
and Ma XM: Epidemiology of myelodysplastic syndromes: Why
characterizing the beast is a prerequisite to taming it. Blood Rev.
34:1–15. 2019. View Article : Google Scholar
|
|
7
|
Corey SJ, Minden MD, Barber DL, Kantarjian
H, Wang JC and Schimmer AD: Myelodysplastic syndromes: The
complexity of stem-cell diseases. Nat Rev Cancer. 7:118–129. 2007.
View Article : Google Scholar
|
|
8
|
Schanz J, Tüchler H, Solé F, Mallo M,
Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki
K, et al: New comprehensive cytogenetic scoring system for primary
myelodysplastic syndromes (MDS) and oligoblastic acute myeloid
leukemia after MDS derived from an international database merge. J
Clin Oncol. 30:820–829. 2012. View Article : Google Scholar
|
|
9
|
Bernasconi P, Klersy C, Boni M, Cavigliano
PM, Calatroni S, Giardini I, Cavigliano PM, Calatroni S, Giardini
I, Rocca B, et al: World Health Organization classification in
combination with cytogenetic markers improves the prognostic
stratification of patients with de novo primary myelodysplastic
syndromes. Br J Haematol. 137:193–205. 2007. View Article : Google Scholar
|
|
10
|
Xiao Y, Wei J, Chen Y, Zhang KJ, Zhou JF
and Zhang YC: Trisomy 8 is the most frequent cytogenetic
abnormality in de novo myelodysplastic syndrome in China.
Onkologie. 35:100–106. 2012. View Article : Google Scholar
|
|
11
|
Wang H, Wang XQ, Xu XP and Lin GW:
Cytogenetic features and prognosis analysis in Chinese patients
with myelodysplastic syndrome: A multicenter study. Ann Hematol.
89:535–544. 2010. View Article : Google Scholar
|
|
12
|
Sole F, Espinet B, Sanz GF, Cervera J,
Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa
JC, et al: Incidence, characterization and prognostic significance
of chromosomal abnormalities in 640 patients with primary
myelodysplastic syndromes. Grupo Cooperativo Español de
Citogenética Hematológica. Br J Haematol. 108:346–356. 2000.
View Article : Google Scholar
|
|
13
|
Matsuda A, Germing U, Jinnai I, Misumi M,
Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H,
et al: Difference in clinical features between Japanese and German
patients with refractory anemia in myelodysplastic syndromes.
Blood. 106:2633–2640. 2005. View Article : Google Scholar
|
|
14
|
Malcovati L, Della Porta MG, Strupp C,
Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R,
Pascutto C, Lazzarino M, et al: Impact of the degree of anemia on
the outcome of patients with myelodysplastic syndromes and its
integration into the WHO classification-based Prognostic Scoring
System (WPSS). Haematologica. 96:1433–1440. 2011. View Article : Google Scholar
|
|
15
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar
|
|
16
|
Seabright M: A rapid banding technique for
human chromosomes. Lancet. 2:971–972. 1971. View Article : Google Scholar
|
|
17
|
Shaffer LG, Slovak ML and Campbell LJ:
ISCN: An International System for Human Cytogenetic Nomenclature.
S. Karger; Basel: 2009
|
|
18
|
Pozdnyakova O, Miron PM, Tang G, Walter O,
Raza A, Woda B and Wang SA: Cytogenetic abnormalities in a series
of 1029 patients with primary myelodysplastic syndromes: A report
from the US with a focus on some undefined single chromosomal
abnormalities. Cancer. 113:3331–3340. 2008. View Article : Google Scholar
|
|
19
|
Germing U, Gattermann N, Strupp C, Aivado
M and Aul C: Validation of the WHO proposals for a new
classification of primary myelodysplastic syndromes: A
retrospective analysis of 1600 patients. Leuk Res. 24:983–992.
2000. View Article : Google Scholar
|
|
20
|
Chen B, Zhao WL, Jin J, Xue YQ, Cheng X,
Chen XT, Cui J, Chen ZM, Cao Q, Yang G, et al: Clinical and
cytogenetic features of 508 Chinese patients with myelodysplastic
syndrome and comparison with those in Western countries. Leukemia.
19:767–775. 2005. View Article : Google Scholar
|
|
21
|
Wu L, Song L, Xu L, Chang C, Xu F, Wu D,
He Q, Su J, Zhou L, Xiao C, et al: Genetic landscape of recurrent
ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese
patients with myelodysplastic syndromes. Tumour Biol. 37:4633–4640.
2016. View Article : Google Scholar
|
|
22
|
Lai YY, Huang XJ, Li J, Zou P, Xu ZF, Sun
H, Shao ZH, Zhou DB, Chen FP, Liu ZG, et al: Standardized
fluorescence in situ hybridization testing based on an appropriate
panel of probes more effectively identifies common cytogenetic
abnormalities in myelodysplastic syndromes than conventional
cytogenetic analysis: A multicenter prospective study of 2302
patients in China. Leuk Res. 39:530–535. 2015. View Article : Google Scholar
|
|
23
|
Haase D, Germing U, Schanz J, Pfeilstöcker
M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R,
Giagounidis AA, et al: New insights into the prognostic impact of
the karyotype in MDS and correlation with subtypes: Evidence from a
core dataset of 2124 patients. Blood. 110:4385–4395. 2007.
View Article : Google Scholar
|
|
24
|
Qu S, Xu Z, Zhang Y, Qin T, Cui R and Xiao
Z: Impacts of cytogenetic categories in the Revised International
Prognostic Scoring System on the prognosis of primary
myelodysplastic syndromes: Results of a single-center study. Leuk
Lymphoma. 53:940–946. 2012. View Article : Google Scholar
|
|
25
|
Xu Y, Li Y, Xu Q, Chen Y, Lv N, Jing Y,
Dou L, Bo J, Hou G, Guo J, et al: Implications of mutational
spectrum in myelodysplastic syndromes based on targeted
next-generation sequencing. Oncotarget. 8:82475–82490. 2017.
View Article : Google Scholar
|
|
26
|
Gangat N, Mudireddy M, Lasho TL, Finke CM,
Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA,
Ketterling RP and Tefferi A: Mutations and prognosis in
myelodysplastic syndromes: Karyotype-adjusted analysis of targeted
sequencing in 300 consecutive cases and development of a genetic
risk model. Am J Hematol. 93:691–697. 2018. View Article : Google Scholar
|
|
27
|
Bernasconi P, Klersy C, Boni M, Cavigliano
PM, Giardini I, Rocca B, Zappatore R, Dambruoso I, Calvello C,
Caresana M and Lazzarino M: Does cytogenetic evolution have any
prognostic relevance in myelodysplastic syndromes? A study on 153
patients from a single institution. Ann Hematol. 89:545–551. 2010.
View Article : Google Scholar
|
|
28
|
Willman CL: Molecular genetic features of
myelodysplastic syndromes (MDS). Leukemia. 12 (Suppl 1):S2–S6.
1998.
|
|
29
|
Greenberg PL: Apoptosis and its role in
the myelodysplastic syndromes: Implications for disease natural
history and treatment. Leuk Res. 22:1123–1136. 1998. View Article : Google Scholar
|
|
30
|
Solé F, Luño E, Sanzo C, Espinet B, Sanz
GF, Cervera J, Calasanz MJ, Cigudosa JC, Millà F, Ribera JM, et
al: Identification of novel cytogenetic markers with prognostic
significance in a series of 968 patients with primary
myelodysplastic syndromes. Haematologica. 90:1168–1178. 2005.
|
|
31
|
Kantarjian H, O'Brien S, Ravandi F, Cortes
J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, et al:
Proposal for a new risk model in myelodysplastic syndrome that
accounts for events not considered in the original International
Prognostic Scoring System. Cancer. 113:1351–1361. 2008. View Article : Google Scholar
|
